[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pigmentary-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pigmentary-glaucoma":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100640261","phase-1-topical-insulin-for-glaucoma-ting2-100640261",false,"NCT07619482","Topical Insulin for Glaucoma (TING2)","A Phase 1\u002F2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma","Limited Inclusion Criteria - All Groups:\n\n* Provide written informed consent approved by the appropriate ethics committee\n* Age 18 years or older\n* Understand study procedures and have the ability and willingness to abide by all procedures during the study\n* Capable of providing informed consent\n* Diagnosis of glaucoma\n* Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and\u002For visual field will be selected\n\nLimited Exclusion Criteria - All Groups:\n\n* Pregnant or breastfeeding\n* Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus\n* Inability to perform reliable visual field testing\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study","ALL","18 Years","90 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1\u002F2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.",[28,29,30,31,32],"Open Angle Glaucoma","Primary Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[34,35,36,37,38],"glaucoma","neuroprotection","topical insulin","retinal ganglion cell","EYED-002","NOT_YET_RECRUITING","2026-05-26",{"date":42,"type":43},"2026-06-02","ACTUAL",{"date":45,"type":21},"2026-06",{"date":47,"type":21},"2029-10",{"name":49,"class":50},"Stanford University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":51},"100616257","quality-of-life-after-glaucoma-surgery-evaluating-the-patient-perspective-across-surgical-options-100616257","NCT07303257","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options - G-SCOPE (Glaucoma Surgery - Comparative Patient Evaluation)","G-SCOPE","Inclusion Criteria:\n\n* Patient aged ≥ 18 years with an indication for glaucoma surgical treatment\n* Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C\n* Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages\n* Pseudoxexfoliative or pigmentary glaucoma\n* Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma\n* Written informed consent obtained prior to study participation\n\nExclusion Criteria:\n\n* Congenital glaucoma\n* Refractory glaucoma with a history of multiple previous surgeries\n* Ophthalmologic surgery within 6 months prior to inclusion\n* Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions)\n* Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period\n* Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study\n* Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder.\n* Patients under curatorship or guardianship\n* Pregnant women",{"count":61,"type":21},132,"OBSERVATIONAL","Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments.\n\nHowever, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques.\n\nFurthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being.\n\nThis study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery.\n\nThe study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.",[65,66,67,68,31],"Glaucoma Eye","Open-angle Glaucoma","Closed-Angle Glaucoma","Pseudo Exfoliative Syndrome",[70,71,72,73,74,75,76,77],"Glaucoma","Trabeculectomy","Sclerectomy","PreserFlo® Micro Shunt","Quality of life","Glaucome Surgery","MIGS","NEI-VFQ 25 (National Eye Institute- Visual Function Questionnaire 25)","RECRUITING","2026-03-12",{"date":81,"type":43},"2026-03-16",{"date":83,"type":43},"2026-02-23",{"date":85,"type":21},"2027-08",{"name":87,"class":50},"Hospices Civils de Lyon",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":51},"100610487","phase-4-standalone-istent-infinite-and-idose-tr-for-management-of-moderate-to-severe-open-angle-glaucoma-100610487","NCT07228221","Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma","iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)","POAG","Inclusion Criteria:\n\n* Moderate to severe open angle glaucoma (including POAG, PG, and PXG)\n* Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9\n* Visual acuity HM or better\n* VF MD -6dB or worse\n* Failed medical therapy and\u002For laser treatment\n* Incisional glaucoma surgery contemplated as next intervention\n* Phakic or pseudophakic\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma\n* Previous incisional glaucoma surgery\n* ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days\n* Active ocular inflammation or edema, clinically significant corneal dystrophy\n* Corneal or other pathology preventing accurate Goldmann applanation tonometry",{"count":97,"type":21},20,[99],"PHASE4","The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.",[28,31,32],[94,103,104],"PG","PXG","2025-11-13",{"date":107,"type":43},"2025-11-14",{"date":109,"type":21},"2026-01-05",{"date":111,"type":21},"2031-12-31",{"name":113,"class":50},"Jonathon Myers"]